Dual targeting of tumor cells with bispecific single-chain fv-immunoliposomes

Antibodies

Volumn 1, Issue 2, 2012, Pages 199-214

  Mack, Katharina ^a   Rüger, Ronny ^b   Fellermeier, Sina ^a   Seifert, Oliver ^a   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Bispecific immunoliposomes; Dual targeting; Single chain Fv fragments; Tumor targeting

Indexed keywords

EID: 84894959120     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib1020199     Document Type: Article

References (45)

1. Fenske, D.B.; Cullis, P.R. Liposomal nanomedicines. Expert Opin. Drug. Deliv. 2008, 5, 25–44.
2. Malam, Y.; Loizidou, M.; Seifalian, A.M. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30, 592–599.
3. Buse, J.; El-Aneed, A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: Current research and advances. Nanomedicine 2010, 5, 1237–1260.
4. Al-Jamal, W.T.; Kostarelos, K. Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 2011, 44, 1094–1104.
5. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760.
6. Gabizon, A.; Shmeeda, H.; Grenader, T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur. J. Pharm. Sci. 2012, 45, 388–398.
7. Woodle, M.C. Sterically stabilized liposome therapeutics. Adv. Drug Deliv. Rev. 1995, 16, 249–265.
8. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42, 463–478.
9. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug. Chem. 2010, 21, 797–802.
10. Jain, R.K.; Styllanopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7, 653–664.
11. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001, 53, 283–318.
12. Bryne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug. Deliv. Rev. 2008, 60, 1615–1626.
13. Wang, M.; Thanou, M. Targeting nanoparticles to cancer. Pharmacol. Res. 2010, 62, 90–99.
14. Maruyama, K.; Ishida, O.; Takizawa, T.; Moribe, K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev. 1999, 40, 89–102.
15. Kontermann, R.E. Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 2006, 8, 39–45.
16. Torchilin, V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug. Deliv. 2008, 5, 1003–1025.
17. Ishida, T.; Iden, D.L.; Allen, T.M. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999, 460, 129–133.
18. Nielsen, U.B.; Kirpotin, D.B.; Pickering, E.M.; Hong, K.; Park, J.W.; Shalaby, M.R.; Shao, Y.; Benz, C.C.; Marks, J.D. Therapeutic efficacy of anti-erbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 2002, 1591, 109–118.
19. Baum, P.; Müller, D.; Rüger, R.; Kontermann, R.E. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J. Drug Target. 2007, 15, 399–406.
20. Messerschmidt, S.K.E.; Kolbe, A.; Müller, D.; Knoll, M.; Pleiss, J.; Kontermann, R.E. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug. Chem. 2008, 19, 362–369.
21. Chhieng, D.C.; Frost, A.R.; Niwas, S.; Weiss, H.; Grizzle, W.E.; Beeken, S. Intratumoral heterogeneity of biomoarker expression in breast carcinomas. Biotech. Histochem. 2004, 79, 25–36.
22. Campbell, L.L.; Polyak, K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007, 6, 2332–2338.
23. Torres, L.; Ribeiro, F.R.; Pandis, N.; Andersen, J.A.; Heim, S.; Teixeira, M.R. Intratumor genomic heterogenity in breast cancer with clonal divergence between primary carcinomas and lymph node metastasis. Breast Cancer Res. Treat. 2007, 102, 143–155.
24. Nassar, A.; Radhakrishnan, A.; Cabrero, I.A.; Cotsonis, G.A.; Cohen, C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 2010, 18, 433–441.
25. Marusyk, A.; Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 2010, 1805, 105–117.
26. Kontermann, R.E. Dual targeting strategies using bispecific antibodies. mAbs 2012, 4, 182–197.
27. Laginha, K.; Mumbengegwi, D.; Allen, T. Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity. Biochem. Biophys. Acta 2005, 1711, 25–32.
28. Ferrante, E.A.; Pickard, J.E.; Rychak, J.; Klibanov, A.; Ley, K. Dual targeting improves microbubble contras agent adhesion to VCAM-1 and P-selectin under flow. J. Control. Release 2009, 140, 100–107.
29. Meng, S.; Su, B.; Li, W.; Ding, Y.; Tang, L.; Zhou, W.; Song, Y.; Li, H.; Zhou, C. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology 2010, 21, 415103.
30. Chen, H.; Yuan, B.; Yang, Z. Dual targeting of glioma U251 cells with nanoparticles prevents tumor angiogenesis and inhibits tumor growth. Curr. Neurovasc. Res. 2012, Epup ahead of print.
31. Saul, J.M.; Annapragada, A.V.; Bellamkonda, R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 2006, 114, 277–287.
32. Rocha-Lima, C.M.; Soares, H.P.; Raez, L.E.; Singal, R. EGFR targeting of solid tumors. Cancer Control 2007, 14, 295–304.
33. Wieduwilt, M.J.; Moasser, M.M. The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol. Life Sci. 2008, 65, 1566–1584.
34. Hammarström, S. The carcinoembryonic antigen (CEA) family: Structure, suggested fucntions and expression in normal and malignant tissues. Semin. Cancer Biol. 1999, 9, 67–81.
35. Rüger, R.; Müller, D.; Fahr, A.; Kontermann, R.E. Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J. Drug Target. 2005, 13, 399–406.
36. Kastantin, M.; Ananthanarayanan, B.; Karmali, P.; Ruoslahti, E.; Tirrell, M. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir 2009, 25, 7279–7286.
37. Iden, D.L.; Allen, T.M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta 2001, 1513, 207–216.
38. Allen, T.M.; Sapra, P.; Moase, E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell. Mol. Biol. Lett. 2002, 7, 889–894.
39. Arleth, L.; Ashok, B.; Onyuksel, H.; Thiyagarajan, P.; Jacob, J.; Hjelm, R.P. Detailed structure of hairy mixed micelles fomred by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 2005, 21, 3279–3290.
40. Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23, 1147–1157.
41. Deonarain, M.P.; Kousparou, C.A.; Epenetos, A.A. Antibodies targeting cancer stem cells: A new paradigm in immunotherapy? mAbs 2005, 1, 12–27.
42. Schliemann, C.; Neri, D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 2010, 180, 201–216.
43. Gunawan, R.C.; Almeda, D.; Augute, D.T. Complementary targeting of liposomes to IL-1a and TNF-a activated endothelial cells via the transient expression of VCAM1 and E-selectin. Biomaterials 2011, 32, 9848–9853.
44. Gunawan, R.C.; Auguste, D.T. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes. Biomaterials 2010, 31, 900–907.
45. Gunawan, R.C.; Auguste, D.T. Immunoliposomes that targeted endothelium in vitro are dependent on lipid raft formation. Mol. Pharma. 2010, 7, 1569–1575.